Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) on November 2, 2021. The report discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors expanded from six to seven members with the appointment of Cary J. Claiborne as a Class I director.
- Compensation Grant: Mr. Claiborne was awarded an option to purchase 60,000 shares of common stock at an exercise price of $3.15 per share.
- Vesting Terms: The stock options vest pro rata on a monthly basis over a 36-month period and are exercisable for ten years from the grant date.
- Cash Retainer: Mr. Claiborne will receive a cash retainer for Board service and committee service in accordance with company policy.
Management Commentary and Background
Mr. Claiborne brings significant experience in the pharmaceutical and finance sectors. His background includes serving as CFO and board member of Indivior PLC (2014–2018), where he led the company's spin-off from Reckitt Benckiser. He previously served as CFO for Sucampo Pharmaceuticals, Inc. and Osiris Therapeutics, Inc. He is currently the CEO of Prosperity Capital Management, LLC, a firm he founded in 2001. The filing confirms no family relationships between Mr. Claiborne and existing directors or officers and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 60,000 new options granted.
- Review the Company's existing stock option plan to confirm the availability of shares for this grant.
- Confirm the specific cash retainer amounts for Board and committee service in the Company's most recent proxy statement or annual report.
- Monitor the Company's 2022 Annual Meeting of Stockholders for the election of Mr. Claiborne to his full term.